Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by ...

Value stocks come into 2025 with some momentum. While the annual returns versus growth stocks paled in comparison, value stocks closed the gap somewhat in the second half. Over the past six months, ...

What is the outlook of the Nasdaq 100 index in 2025? We explain the risk and opportunities and what to expect in the coming ...